{"version":"1.0","provider_name":"Times South Africa","provider_url":"https:\/\/timessouthafrica.com","author_name":"TSA","author_url":"https:\/\/timessouthafrica.com\/author\/tsa\/","title":"Zenas BioPharma Publica Fase 2 do Estudo Cl\u00ednico do Obexelimabe, um Tratamento Investigativo da Doen\u00e7a Relacionada \u00e0 IgG4 (IgG4-RD), no The Lancet Rheumatology - Times South Africa","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"ICIT9vVzmM\"><a href=\"https:\/\/timessouthafrica.com\/zenas-biopharma-publica-fase-2-do-estudo-clinico-do-obexelimabe-um-tratamento-investigativo-da-doenca-relacionada-a-igg4-igg4-rd-no-the-lancet-rheumatology\/\">Zenas BioPharma Publica Fase 2 do Estudo Cl\u00ednico do Obexelimabe, um Tratamento Investigativo da Doen\u00e7a Relacionada \u00e0 IgG4 (IgG4-RD), no The Lancet Rheumatology<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/timessouthafrica.com\/zenas-biopharma-publica-fase-2-do-estudo-clinico-do-obexelimabe-um-tratamento-investigativo-da-doenca-relacionada-a-igg4-igg4-rd-no-the-lancet-rheumatology\/embed\/#?secret=ICIT9vVzmM\" width=\"600\" height=\"338\" title=\"&#8220;Zenas BioPharma Publica Fase 2 do Estudo Cl\u00ednico do Obexelimabe, um Tratamento Investigativo da Doen\u00e7a Relacionada \u00e0 IgG4 (IgG4-RD), no The Lancet Rheumatology&#8221; &#8212; Times South Africa\" data-secret=\"ICIT9vVzmM\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Estudo revelou que o obexelimabe produziu melhora cl\u00ednica r\u00e1pida, forte e sustentada, incluindo remiss\u00e3o cl\u00ednica completa, na maioria dos pacientes com IgG4-RD ativa Os resultados apoiam o desenvolvimento cont\u00ednuo do obexelimabe para o tratamento de IgG4-RD e potencialmente outras condi\u00e7\u00f5es autoimunes mediadas por c\u00e9lulas B WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) \u2014 A Zenas [\u2026]","thumbnail_url":"https:\/\/ci4.googleusercontent.com\/proxy\/b3ktj7eekSID7SR8lSj_dNTKBxrSuufZrKAqvIQW_mvhFOMbPEB4HaLheCw3V7FGT3Kcg7BpZgQDzBpD1WppBDK5V7n-euz2dnoP05pMeZoz4sOIrG8PBVl-1tff6lWuRuN1taJQFBzqXzWoiExDqZX80UsAP24bXzq6JiswMUhpnxTJsldzZbrZ1Es3GtMGMwp1xw=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MDFmZTFlZjEtOWYyMi00NGM0LWE2NGUtYjM0ZTczMGUzMzI0LTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png"}